Screener
Novavax NVAX Operating Income
Operating Income at other companies
Other financials
Where this comes from
Reported directly by Novavax in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The source filing: Novavax’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 7:50 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001000694-26-000018
| Line item | For the Three Months Ended June 30, 2026 | For the Three Months Ended June 30, 2025 | For the Six Months Ended June 30, 2026 | For the Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Research and development | 70,693 | 79,233 | 166,165 | 168,170 |
| Selling, general, and administrative | 26,665 | 43,612 | 55,442 | 91,702 |
| Total expenses | 111,604 | 138,170 | 266,548 | 289,311 |
| Income (loss) from operations | (54,906) | 101,070 | (70,336) | 616,584 |
| Other income (expense): | ||||
| Interest expense | (5,689) | (5,518) | (10,590) | (11,241) |
| Other income, net | 8,919 | 11,902 | 20,744 | 21,957 |
| Income (loss) before income tax expense | (51,676) | 107,454 | (60,182) | 627,300 |
Item 1. Consolidated Financial Statements
FAQ
- What is Novavax's operating income?
- Novavax (NVAX) reported operating income of -$54.91M in Q2 2026.
- How has Novavax's operating income changed year-over-year?
- Novavax's operating income decreased by 154.3% year-over-year, from $101.07M to -$54.91M.
- What is the long-term trend for Novavax's operating income?
- Over 4 years (2021 to 2025), Novavax's operating income has grown at a -28.0% compound annual growth rate (CAGR), from -$1.69B to $452.8M.
- What does operating income mean?
- Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.
Ask your AI about Novavax's operating income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude